MX2023000511A - Nanoparticulas lipidicas para administrar agentes terapeuticos en los pulmones. - Google Patents

Nanoparticulas lipidicas para administrar agentes terapeuticos en los pulmones.

Info

Publication number
MX2023000511A
MX2023000511A MX2023000511A MX2023000511A MX2023000511A MX 2023000511 A MX2023000511 A MX 2023000511A MX 2023000511 A MX2023000511 A MX 2023000511A MX 2023000511 A MX2023000511 A MX 2023000511A MX 2023000511 A MX2023000511 A MX 2023000511A
Authority
MX
Mexico
Prior art keywords
lungs
lipid nanoparticles
delivering therapeutics
therapeutics
delivering
Prior art date
Application number
MX2023000511A
Other languages
English (en)
Spanish (es)
Inventor
James Heyes
Kieu Mong Lam
Lorne Ralph Palmer
Original Assignee
Genevant Sciences Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genevant Sciences Gmbh filed Critical Genevant Sciences Gmbh
Publication of MX2023000511A publication Critical patent/MX2023000511A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/713Double-stranded nucleic acids or oligonucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0043Nose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/5123Organic compounds, e.g. fats, sugars
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/513Organic macromolecular compounds; Dendrimers
    • A61K9/5146Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111General methods applicable to biologically active non-coding nucleic acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/14Type of nucleic acid interfering nucleic acids [NA]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00Applications; Uses
    • C12N2320/30Special therapeutic applications
    • C12N2320/32Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
MX2023000511A 2020-07-10 2021-07-08 Nanoparticulas lipidicas para administrar agentes terapeuticos en los pulmones. MX2023000511A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063050594P 2020-07-10 2020-07-10
PCT/US2021/040913 WO2022011156A1 (en) 2020-07-10 2021-07-08 Lipid nanoparticles for delivering therapeutics to lungs

Publications (1)

Publication Number Publication Date
MX2023000511A true MX2023000511A (es) 2023-02-13

Family

ID=79552114

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023000511A MX2023000511A (es) 2020-07-10 2021-07-08 Nanoparticulas lipidicas para administrar agentes terapeuticos en los pulmones.

Country Status (10)

Country Link
US (1) US20240065982A1 (https=)
EP (1) EP4178585A4 (https=)
JP (1) JP2023534206A (https=)
KR (1) KR20230038217A (https=)
CN (1) CN115768438A (https=)
AU (1) AU2021305214A1 (https=)
CA (1) CA3188661A1 (https=)
IL (1) IL299750A (https=)
MX (1) MX2023000511A (https=)
WO (1) WO2022011156A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021005462A (es) * 2018-11-09 2021-08-24 Arbutus Biopharma Corp Lipidos cationicos que contienen silicio.
CZ310613B6 (cs) 2020-09-23 2026-01-28 Ústav organické chemie a biochemie AV ČR, v. v. i. Lipidoidy pro transfekci nukleových kyselin a jejich použití
CZ310443B6 (cs) 2021-07-19 2025-06-25 Ústav organické chemie a biochemie AV ČR, v. v. i. Cyklohexanové lipidoidy pro transfekci nukleových kyselin a jejich použití
CN119654166A (zh) 2022-04-01 2025-03-18 内诺维什疗法股份有限公司 mRNA递送方法及其组合物
KR20250094676A (ko) * 2022-10-25 2025-06-25 나노베이션 테라퓨틱스 인크. 안티-센스 올리고뉴클레오티드 전달을 위한 지질 나노입자 제형
WO2025133951A1 (en) * 2023-12-21 2025-06-26 Genevant Sciences Gmbh Ionizable lipids suitable for lipid nanoparticles
WO2025166323A2 (en) 2024-02-02 2025-08-07 Editas Medicine, Inc. Crispr-related methods and compositions targeting lipoprotein (a) expression
WO2025213138A1 (en) 2024-04-05 2025-10-09 Editas Medicine, Inc. Crispr/rna-guided nuclease related methods and compositions for treating primary open angle glaucoma
CN118576568B (zh) * 2024-08-06 2024-11-26 北京悦康科创医药科技股份有限公司 一种药物组合物及其制备方法和应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009238175C1 (en) * 2008-04-15 2023-11-30 Arbutus Biopharma Corporation Novel lipid formulations for nucleic acid delivery
EP3319976B1 (en) * 2015-07-09 2021-09-01 Insmed Incorporated Compositions and methods for treating lung diseases and lung injury
CA3103528A1 (en) * 2018-06-19 2019-12-26 The Board Of Regents Of The University Of Texas System Lipid nanoparticle compositions for delivery of mrna and long nucleic acids
DE102018127300A1 (de) * 2018-10-31 2020-04-30 Henkel Ag & Co. Kgaa Wirkstoffzusammensetzung zum Schutz künstlich gefärbter Haare
MX2021005462A (es) * 2018-11-09 2021-08-24 Arbutus Biopharma Corp Lipidos cationicos que contienen silicio.
AU2020262437A1 (en) * 2019-04-26 2021-12-23 Genevant Sciences Gmbh Lipid nanoparticles

Also Published As

Publication number Publication date
CN115768438A (zh) 2023-03-07
AU2021305214A1 (en) 2023-02-23
IL299750A (en) 2023-03-01
EP4178585A4 (en) 2024-11-20
WO2022011156A1 (en) 2022-01-13
WO2022011156A9 (en) 2022-03-17
CA3188661A1 (en) 2022-01-13
EP4178585A1 (en) 2023-05-17
KR20230038217A (ko) 2023-03-17
US20240065982A1 (en) 2024-02-29
JP2023534206A (ja) 2023-08-08

Similar Documents

Publication Publication Date Title
MX2023000511A (es) Nanoparticulas lipidicas para administrar agentes terapeuticos en los pulmones.
WO2022032154A3 (en) Compositions for the delivery of payload molecules to airway epithelium
ZA202103233B (en) Lipid nanoparticle formulations
JOP20220037A1 (ar) جسيمات نانوية دهنية محسنة لتوصيل الأحماض النووية
ZA202106265B (en) Compositions and methods for inhibiting gene expression of lpa
MX2024013597A (es) Composiciones de nanoparticulas lipidicas para suministro de agentes biologicamente activos
MX2022007680A (es) Nanoparticulas lipidicas para administracion de acidos nucleicos.
WO2020051220A8 (en) Compositions and methods for organ specific delivery of nucleic acids
NZ718817A (en) Lipid formulations for delivery of messenger rna
MX354618B (es) Sistema de nanopartículas nts-poliplex para terapia génica de cáncer.
MX385048B (es) Composiciones y metodos para inhibir la expresion del gen alas1.
PH12020550195A1 (en) Use of p38 inhibitors to reduce expression of dux4
EP4527463A3 (en) Compositions and methods for the delivery of therapeutics
UA115648C2 (uk) Доставка терапевтичних агентів до цнс
ZA202403360B (en) Lipid nanoparticles for oligonucleotide delivery
PH12019502660A1 (en) RNAi AGENTS FOR INHIBITING EXPRESSION OF ALPHA-ENaC AND METHODS OF USE
MX2016004319A (es) Composiciones y metodos para inhibir la expresion del gen de sintasa de acido 5'-aminolevulinico 1 (alas1).
ZA202403337B (en) Lipid nanoparticles for oligonucleotide delivery
MX385871B (es) Composiciones y metodos para inhibir la expresion del gen lect2.
MY167701A (en) Sublingual administration of statins
EA201591188A1 (ru) Доставка глатирамера ацетата через слизистую оболочку
PH12016500384A1 (en) Formulations of aminoglycosides and fosfomycin in a combination having improved chemical properties
HK40084784A (en) Lipid nanoparticles for delivering therapeutics to lungs
NZ758283A (en) Lipid formulations for delivery of messenger rna
WO2020018049A3 (en) Lipid nanoparticles loaded with ceranib-2 as anticancer agents